Skip to main content

Table 2 Changes in LogMAR BCVA in the three groups of patients

From: The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage

Variables

Group A

Group B

Group C

F

P- value

LogMAR BCVA

 Baseline

2.006 ± 0.427

1.988 ± 0.463

2.05 ± 0.412

0.087

0.917

 Month 3

0.706 ± 0.277

0.488 ± 0.189

0.463 ± 0.159

6.272

0.004